CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$7.79 USD
-0.31 (-3.83%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.80 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRVO 7.79 -0.31(-3.83%)
Will CRVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates
CRVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
Other News for CRVO
Is CRVO poised for a decline? 180 Bearish Setup shows up after sinking 3.83%
Is CRVO set to breakout? NR7 shows up after climbing 3.98%
CRVO forms Lower Bollinger Band Walk on September 17
New Downtrend appears for CRVO after 5.04% move
CervoMed (CRVO) Advances Dementia Treatment with Neflamapimod